Alex Rodriguez

Alex Rodriguez’s 211-game suspension is crazy and should be reduced

152 Comments

The MLBPA’s official statement on the suspensions of the Biogenesis players is something I can totally agree with: the 50-game suspensions make sense given that all involved were first time drug offenders who agreed, when they chose not to appeal, that MLB had the goods on them. But Alex Rodriguez’s 211-game suspension is crazy and it should be reduced.

It’s crazy for a number of reasons.

One simple argument is that A-Rod is receiving discipline for the first time under the Joint Drug Agreement (JDA). The JDA calls for suspensions of 50 games, 100 games or life. A strict constructionist of the JDA could very easily say that A-Rod, as a first offender, should get 50 games, full stop.  Now, I’m not naive. I don’t think that argument will necessarily work. Indeed, the head of the union himself said, for some reason, that the 50-100-life rubric does not apply to Biogenesis cases. I’m not sure why he’d admit that, but I do feel like if that argument had any weight it would have been made a lot more forcefully before now. Still: it’s not an argument I’d abandon if I was A-Rod’s lawyer.

MORE: A-Rod on appeal:’I’m fighting for my life’

A more compelling argument: 211 games is the most arbitrary number imaginable, and arbitrators of employer-employee agreements tend not to like arbitrariness.

The Joint Drug Agreement employs a unit of measurement for drug discipline: games. MLB may make an impassioned and persuasive case that Alex Rodriguez was a horrible wrongdoer, but they clearly chose this discipline based on how long they wanted to see him gone — this season and all of next — and simply calculated how many games that covered. In this sense it was entirely arbitrary and made little effort to match up the severity of the acts with the severity of the punishment. If it happened last week he’d get 217 games? If it happened next week he’d get 205? For the same conduct? It speaks to an unreasonable standard of discipline, even if it happens to go after unreasonably bad behavior.

Let’s talk about that behavior. A-Rod’s Biogenesis case has been the subject of countless leaks over the past several months, and most of those leaks have spoken non-specifically of awful, awful things. We don’t know how awful. Maybe it’s really, really bad! Obstruction of the investigation. Maybe some sort of luring of other players to Tony Bosch’s clinic. We really don’t know.  But we do know that for 211 games to stick, those acts have to be more than four times worse than some other player’s drug use, right? That’s how MLB got to its arbitrary number, right?

MORE: Rodriguez goes 1-for-4 in first game back with Yanks

I don’t know what MLB’s evidence is, but I do know this much: the historic pattern of A-Rod coverage has been to take what he actually did, multiply it by about a million times in terms of severity and report it as the worst thing that ever happened.  Puffing up A-Rod’s evil works with tabloid readers, talk radio callers and the “A-Rod is the devil” folks, but it’s unlikely to work well with an arbitrator. So if that pattern is happening once again, it may be a much closer case than many are portraying.

None of that means Alex Rodriguez didn’t do anything wrong. None of that means that Alex Rodriguez will succeed on his appeal. But from where I’m sitting, Major League Baseball’s 211-game suspension looks hard to defend, and it’s hard to blame Rodriguez for going after it on appeal.

Danny Espinosa reportedly skipped Nationals Winterfest because of Adam Eaton

WASHINGTON, DC - OCTOBER 13: Danny Espinosa #8 of the Washington Nationals celebrates after teammate Chris Heisey #14 (not pictured) hits a two run home run in the seventh inning against the Los Angeles Dodgers during game five of the National League Division Series at Nationals Park on October 13, 2016 in Washington, DC. (Photo by Rob Carr/Getty Images)
Getty Images
7 Comments

According to Jorge Castillo of the Washington Post, Nationals infielder Danny Espinosa declined to attend the team’s annual Winterfest because of his dissatisfaction with management following their trade for outfielder Adam Eaton.

A source told Castillo that Espinosa’s unhappiness stemmed from a belief that the acquisition would jeopardize his starting role in 2017. With Eaton in center field, Trea Turner will likely return to his post at shortstop, leaving Espinosa out in the cold — or, as the case may be, on the bench. The move shouldn’t come as a big surprise to Espinosa, however, as Nationals’ GM Mike Rizzo spoke to the possibility of trading the infielder or reassigning him to a utility role back in early November.

Offensively, the 29-year-old had a down year in 2016, slashing just .209/.306/.378 with 24 home runs in 601 PA. Defensively, he still profiles among the top shortstops in the National League, with eight DRS (Defensive Runs Saved) and 8.3 Def (Defensive Runs Above Average) in his seventh year with the club.

Espinosa will reach free agency after the 2017 season.

Nick Cafardo: Red Sox should deal Pomeranz, not Buchholz

BOSTON, MA - SEPTEMBER 18: Drew Pomeranz #31 of the Boston Red Sox pitches during the first inning against the New York Yankees at Fenway Park on September 18, 2016 in Boston, Massachusetts. The Red Sox won 5-4. (Photo by Rich Gagnon/Getty Images)
Getty Images
9 Comments

The Red Sox might be trying to move the wrong pitcher, according to the Boston Globe’s Nick Cafardo. Cafardo revealed that while the Sox have been trying to market right-hander Clay Buchholz, more teams would be interested in trades involving southpaw Drew Pomeranz.

The club appears reluctant to deal Pomeranz, especially because his price tag comes in at a cool $4.7 million to Buchholz’s $13.5 million in 2017. Those who have already expressed interest in the veteran hurlers, including the Twins, Mariners and Royals, also seem put off by Buchholz’s salary requirements as he enters his 32nd year.

Health could be another factor preventing teams from jumping to make trade offers, as Cafardo quotes an AL executive who believes the “medicals on both Pomeranz and Buchholz probably aren’t that great.” Neither pitcher suffered any major injuries during the 2016 season, though Pomeranz missed just over a week of play due to forearm soreness.

Pomeranz outperformed his fellow starter in 2016, pitching to a 3.32 ERA and career-best 9.8 K/9 through 170 2/3 innings with the Padres and Red Sox. He got off to an exceptionally strong start in San Diego, where his ERA dropped to 2.47 through the first half of the year before the Padres dealt him to Boston for minor league right-hander Anderson Espinoza. Buchholz, on the other hand, struggled with a 4.78 ERA and saw a decline in both his BB/9 and K/9 rates as he worked out a career-low 1.69 K/BB through 139 1/3 innings with the Sox.